메뉴 건너뛰기




Volumn 18, Issue 1, 2012, Pages 152-160

Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GEMCITABINE; IMMUNOTOXIN LMB2; INTERLEUKIN 2 RECEPTOR ALPHA;

EID: 84855431169     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1839     Document Type: Article
Times cited : (20)

References (49)
  • 1
    • 70449347055 scopus 로고    scopus 로고
    • Approach to the patient after relapse of hairy cell leukemia
    • Kreitman RJ, Fitzgerald DJ, Pastan I. Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma 2009;50 Suppl 1:32-7.
    • (2009) Leuk Lymphoma , vol.50 , Issue.SUPPL. 1 , pp. 32-37
    • Kreitman, R.J.1    Fitzgerald, D.J.2    Pastan, I.3
  • 3
    • 0018167496 scopus 로고
    • One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
    • Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978;15:245-50. (Pubitemid 9027527)
    • (1978) Cell , vol.15 , Issue.1 , pp. 245-250
    • Yamaizumi, M.1    Mekada, E.2    Uchida, T.3    Okada, Y.4
  • 5
    • 0034001076 scopus 로고    scopus 로고
    • Phase I trial of recombinant immunotoxin Anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies
    • Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Waldmann TA, et al. Phase I trial of recombinant immunotoxin Anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1614-36.
    • (2000) J Clin Oncol , vol.18 , pp. 1614-1636
    • Kreitman, R.J.1    Wilson, W.H.2    White, J.D.3    Stetler-Stevenson, M.4    Jaffe, E.S.5    Waldmann, T.A.6
  • 9
    • 0024349836 scopus 로고
    • A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
    • DOI 10.1038/339394a0
    • Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989;339:394-7. (Pubitemid 19144230)
    • (1989) Nature , vol.339 , Issue.6223 , pp. 394-397
    • Chaudhary, V.K.1    Queen, C.2    Junghans, R.P.3    Waldmann, T.A.4    FitzGerald, D.J.5    Pastan, I.6
  • 10
    • 0027572639 scopus 로고
    • Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: Relative importance of the two toxin disulfide bonds
    • Kreitman RJ, Batra JK, Seetharam S, Chaudhary VK, FitzGerald DJ, Pastan I. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconjug Chem 1993;4:112-20.
    • (1993) Bioconjug Chem , vol.4 , pp. 112-120
    • Kreitman, R.J.1    Batra, J.K.2    Seetharam, S.3    Chaudhary, V.K.4    FitzGerald, D.J.5    Pastan, I.6
  • 11
    • 0019421207 scopus 로고
    • A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
    • Uchiyama TA, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981;126:1393-7. (Pubitemid 11149233)
    • (1981) Journal of Immunology , vol.126 , Issue.4 , pp. 1393-1397
    • Uchiyama, T.1    Broder, S.2    Waldmann, T.A.3
  • 12
    • 77949679970 scopus 로고    scopus 로고
    • Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: Preclinical studies and phase I clinical trial
    • Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 2010;16:1894-903.
    • (2010) Clin Cancer Res , vol.16 , pp. 1894-1903
    • Wayne, A.S.1    Kreitman, R.J.2    Findley, H.W.3    Lew, G.4    Delbrook, C.5    Steinberg, S.M.6
  • 13
    • 0033521739 scopus 로고    scopus 로고
    • 111Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a humancarcinoma xenograft expressing mesothelin
    • 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a humancarcinoma xenograft expressing mesothelin. Int J Cancer 1999;80:559-63.
    • (1999) Int J Cancer , vol.80 , pp. 559-563
    • Hassan, R.1    Wu, C.2    Brechbiel, M.W.3    Margulies, I.4    Kreitman, R.J.5    Pastan, I.6
  • 14
    • 0033936583 scopus 로고    scopus 로고
    • Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma
    • DOI 10.1097/00002371-200007000-00011
    • Hassan R, Viner J, Wang QC, Kreitman RJ, Pastan I. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin-targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother 2000;23:473-9. (Pubitemid 30457705)
    • (2000) Journal of Immunotherapy , vol.23 , Issue.4 , pp. 473-479
    • Hassan, R.1    Viner, J.L.2    Wang, Q.-C.3    Margulies, I.4    Kreitman, R.J.5    Pastan, I.6
  • 15
    • 34548858453 scopus 로고    scopus 로고
    • Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
    • DOI 10.1158/1078-0432.CCR-07-0869
    • Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham M, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9. (Pubitemid 47502082)
    • (2007) Clinical Cancer Research , vol.13 , Issue.17 , pp. 5144-5149
    • Hassan, R.1    Bullock, S.2    Premkumar, A.3    Kreitman, R.J.4    Kindler, H.5    Willingham, M.C.6    Pastan, I.7
  • 16
    • 69349100450 scopus 로고    scopus 로고
    • Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P
    • Kreitman RJ, Hassan R, FitzGerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-9.
    • (2009) Clin Cancer Res , vol.15 , pp. 5274-5279
    • Kreitman, R.J.1    Hassan, R.2    FitzGerald, D.J.3    Pastan, I.4
  • 18
    • 58149331196 scopus 로고    scopus 로고
    • High shed antigen levels within tumors: An additional barrier to immunoconjugate therapy
    • Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res 2008;14:7981-6.
    • (2008) Clin Cancer Res , vol.14 , pp. 7981-7986
    • Zhang, Y.1    Pastan, I.2
  • 19
    • 37249025607 scopus 로고    scopus 로고
    • Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts
    • DOI 10.1158/1078-0432.CCR-07-1592
    • Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J. Antimesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 2007;13:7166-71. (Pubitemid 350276903)
    • (2007) Clinical Cancer Research , vol.13 , Issue.23 , pp. 7166-7171
    • Hassan, R.1    Broaddus, V.C.2    Wilson, S.3    Liewehr, D.J.4    Zhang, J.5
  • 21
    • 0032032442 scopus 로고    scopus 로고
    • Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient for complete responses
    • Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 1998;58:968-75. (Pubitemid 28182466)
    • (1998) Cancer Research , vol.58 , Issue.5 , pp. 968-975
    • Kreitman, R.J.1    Pastan, I.2
  • 22
    • 0034061246 scopus 로고    scopus 로고
    • Recombinant anti-CD25 immunotoxin RFT5(scFv)-ETA' demonstrates successful elimination of disseminated human hodgkin lymphoma in SCID mice
    • DOI 10.1002/(SICI)1097-0215(20000601)86:5<718::AID-IJC18>3.0.CO;2-N
    • Barth S, Huhn M, Matthey B, Schnell R, Tawadros S, Schinkothe T, et al. Recombinant anti-CD25 immunotoxin RFT5(ScFv)-ETA′ demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Int J Cancer 2000;86:718-24. (Pubitemid 30249885)
    • (2000) International Journal of Cancer , vol.86 , Issue.5 , pp. 718-724
    • Barth, S.1    Huhn, M.2    Matthey, B.3    Schnell, R.4    Tawadros, S.5    Schinkothe, T.6    Lorenzen, J.7    Diehl, V.8    Engert, A.9
  • 23
    • 0034659745 scopus 로고    scopus 로고
    • Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated hodgkin tumors in SCID mice
    • Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T, et al. Ki-4(scFv)-ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000;95:3909-14. (Pubitemid 30412867)
    • (2000) Blood , vol.95 , Issue.12 , pp. 3909-3914
    • Barth, S.1    Huhn, M.2    Matthey, B.3    Tawadros, S.4    Schnell, R.5    Schinkothe, T.6    Diehl, V.7    Engert, A.8
  • 24
    • 0028070359 scopus 로고
    • Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody Bi-212-Anti-Tac
    • Hartmann F, Horak EM, Garmestani K, Wu CC, Brechbiel MW, Kozak RW, et al. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody Bi-212-Anti-Tac. Cancer Res 1994;54:4362-70.
    • (1994) Cancer Res , vol.54 , pp. 4362-4370
    • Hartmann, F.1    Horak, E.M.2    Garmestani, K.3    Wu, C.C.4    Brechbiel, M.W.5    Kozak, R.W.6
  • 25
    • 0028057249 scopus 로고
    • Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma
    • Kreitman RJ, Bailon P, Chaudhary VK, FitzGerald DJP, Pastan I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood 1994;83:426-34. (Pubitemid 24030568)
    • (1994) Blood , vol.83 , Issue.2 , pp. 426-434
    • Kreitman, R.J.1    Ballon, P.2    Chaudhary, V.K.3    FitzGerald, D.J.P.4    Pastan, I.5
  • 26
    • 0032127605 scopus 로고    scopus 로고
    • Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF
    • DOI 10.1021/bc980015a
    • Frankel AE, Hall PD, McLain C, Safa AR, Tagge EP, Kreitman RJ. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug Chem 1998;9:490-6. (Pubitemid 28338764)
    • (1998) Bioconjugate Chemistry , vol.9 , Issue.4 , pp. 490-496
    • Frankel, A.E.1    Hall, P.D.2    McLain, C.3    Safa, A.R.4    Tagge, E.P.5    Kreitman, R.J.6
  • 27
    • 0033000042 scopus 로고    scopus 로고
    • Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells
    • DOI 10.1016/S0145-2126(99)00039-9, PII S0145212699000399
    • Kim CN, Bhalla K, Kreitman RJ, Willingham MC, Hall P, Tagge EP, et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leuk Res 1999;23:527-38. (Pubitemid 29258052)
    • (1999) Leukemia Research , vol.23 , Issue.6 , pp. 527-538
    • Kim, C.N.1    Bhalla, K.2    Kreitman, R.J.3    Willingham, M.C.4    Hall, P.5    Tagge, E.P.6    Jia, T.7    Frankel, A.E.8
  • 28
    • 0000994406 scopus 로고
    • Analysis of combined drug effects: A new look at a very old problem
    • Chou T, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharm Sci 1983;4:450.
    • (1983) Trends Pharm Sci , vol.4 , pp. 450
    • Chou, T.1    Talalay, P.2
  • 30
    • 0022628282 scopus 로고
    • In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: Relevance to immunotherapy of prostate carcinoma
    • Webb KS, Liberman SN, Ware JL, Walther PJ. In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma. Cancer Immunol Immunother 1986;21:100-6. (Pubitemid 16155055)
    • (1986) Cancer Immunology, Immunotherapy , vol.21 , Issue.2 , pp. 100-106
    • Webb, K.S.1    Liberman, S.N.2    Ware, J.L.3    Walther, P.J.4
  • 31
  • 32
    • 3142780741 scopus 로고    scopus 로고
    • The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine
    • DOI 10.1038/sj.leu.2403378
    • Polito L, Bolognesi A, Tazzari PL, Farini V, Lubelli C, Zinzani PL, et al. The conjugate rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with fludarabine. Leukemia 2004;18:1215-22. (Pubitemid 39023131)
    • (2004) Leukemia , vol.18 , Issue.7 , pp. 1215-1222
    • Polito, L.1    Bolognesi, A.2    Tazzari, P.L.3    Farini, V.4    Lubelli, C.5    Zinzani, P.L.6    Ricci, F.7    Stirpe, F.8
  • 33
    • 0036527011 scopus 로고    scopus 로고
    • Synergistic cytotoxic effect of immunotoxin HEL-PE38KDEL and cisplatin against tumor cells
    • Wang JS, Wang SM, Chen GR, Yang DJ. [Synergistic cytotoxic effect of immunotoxin HEL-PE38KDEL and cisplatin against tumor cells]. Ai Zheng 2002;21:360-3.
    • (2002) Ai Zheng , vol.21 , pp. 360-363
    • Wang, J.S.1    Wang, S.M.2    Chen, G.R.3    Yang, D.J.4
  • 34
    • 0026570575 scopus 로고
    • Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: In vitro and in vivo studies
    • Griffin TW, Stocl M, Collins J, Fernandes J, Maher VE. Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies. J Immunother (1991) 1992;11:12-8.
    • (1992) J Immunother (1991) , vol.11 , pp. 12-18
    • Griffin, T.W.1    Stocl, M.2    Collins, J.3    Fernandes, J.4    Maher, V.E.5
  • 35
    • 0029923246 scopus 로고    scopus 로고
    • Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs
    • Liu C, Lambert JM, Teicher BA, Blattler WA, O'Connor R. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood 1996;87:3892-8. (Pubitemid 26129619)
    • (1996) Blood , vol.87 , Issue.9 , pp. 3892-3898
    • Liu, C.1    Lambert, J.M.2    Teicher, B.A.3    Blattler, W.A.4    O'Connor, R.5
  • 36
    • 0028885812 scopus 로고
    • Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors
    • O'Connor R, Liu C, Ferris CA, Guild BC, Teicher BA, Corvi C, et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 1995;86:4286-94.
    • (1995) Blood , vol.86 , pp. 4286-4294
    • O'Connor, R.1    Liu, C.2    Ferris, C.A.3    Guild, B.C.4    Teicher, B.A.5    Corvi, C.6
  • 37
    • 0024420679 scopus 로고
    • Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice
    • Pearson JW, Sivam G, Manger R, Wiltrout RH, Morgan AC Jr, Longo DL. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res 1989;49:4990-5. (Pubitemid 19239331)
    • (1989) Cancer Research , vol.49 , Issue.18 , pp. 4990-4995
    • Pearson, J.W.1    Sivam, G.2    Manger, R.3    Wiltrout, R.H.4    Morgan Jr., A.C.5    Longo, D.L.6
  • 38
    • 0025128963 scopus 로고
    • Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin
    • Yokota S, Hara H, Luo Y, Seon BK. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin. Cancer Res 1990;50:32-7. (Pubitemid 20029989)
    • (1990) Cancer Research , vol.50 , Issue.1 , pp. 32-37
    • Yokota, S.1    Hara, H.2    Luo, Y.3    Seon, B.K.4
  • 39
    • 0029135360 scopus 로고
    • Increased antitumor activity of a circularly permuted interleukin 4-toxin inmice with interleukin 4 receptor-bearing human carcinoma
    • Kreitman RJ, Puri RK, Pastan I. Increased antitumor activity of a circularly permuted interleukin 4-toxin inmice with interleukin 4 receptor-bearing human carcinoma. Cancer Res 1995;55:3357-63.
    • (1995) Cancer Res , vol.55 , pp. 3357-3363
    • Kreitman, R.J.1    Puri, R.K.2    Pastan, I.3
  • 40
    • 35448930671 scopus 로고    scopus 로고
    • Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma
    • DOI 10.1158/0008-5472.CAN-06-4558
    • Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res 2007;67:9903-12. (Pubitemid 47621239)
    • (2007) Cancer Research , vol.67 , Issue.20 , pp. 9903-9912
    • Shimamura, T.1    Royal, R.E.2    Kioi, M.3    Nakajima, A.4    Husain, S.R.5    Puri, R.K.6
  • 41
    • 22144495793 scopus 로고    scopus 로고
    • A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma
    • DOI 10.1182/blood-2004-11-4570
    • Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005;106:454-7. (Pubitemid 40981237)
    • (2005) Blood , vol.106 , Issue.2 , pp. 454-457
    • Foss, F.1    Demierre, M.F.2    DiVenuti, G.3
  • 42
    • 0026739369 scopus 로고
    • Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier
    • Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-53.
    • (1992) Cancer Res , vol.52 , pp. 5144-5153
    • Juweid, M.1    Neumann, R.2    Paik, C.3    Perez-Bacete, M.J.4    Sato, J.5    Van Osdol, W.6
  • 43
    • 33646366039 scopus 로고    scopus 로고
    • Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin, LMB-2
    • Attia P, Powell DJ Jr, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin, LMB-2. J Immunother 2006;29:208-14.
    • (2006) J Immunother , vol.29 , pp. 208-214
    • Attia, P.1    Powell Jr., D.J.2    Maker, A.V.3    Kreitman, R.J.4    Pastan, I.5    Rosenberg, S.A.6
  • 44
    • 40749114476 scopus 로고    scopus 로고
    • Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
    • Powell DJ, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007;179:4919-28.
    • (2007) J Immunol , vol.179 , pp. 4919-4928
    • Powell, D.J.1    Felipe-Silva, A.2    Merino, M.J.3    Ahmadzadeh, M.4    Allen, T.5    Levy, C.6
  • 47
    • 24944462403 scopus 로고    scopus 로고
    • Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I-131 tositumomab for untreated follicular lymphoma
    • Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I-131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696-704.
    • (2005) J Clin Oncol , vol.23 , pp. 5696-5704
    • Leonard, J.P.1    Coleman, M.2    Kostakoglu, L.3    Chadburn, A.4    Cesarman, E.5    Furman, R.R.6
  • 48
    • 0036754115 scopus 로고    scopus 로고
    • Gemcitabine and its combinations in the treatment of malignant lymphoma
    • Chau I, Watkins D, Cunningham D. Gemcitabine and its combinations in the treatment of malignant lymphoma. Clin Lymphoma 2002;3:97-104. (Pubitemid 35277015)
    • (2002) Clinical Lymphoma , vol.3 , Issue.2 , pp. 97-104
    • Chau, I.1    Watkins, D.2    Cunningham, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.